Tech Company Inital Public Offerings
Moderna IPO
Moderna, operating out of Cambridge, debuted as a public company on 12/6/2018.
Transaction Overview
Company Name
Announced On
12/6/2018
Transaction Type
IPO
Amount
$598,000,000
Proceeds Purpose
Proceeds will be used as follows: approximately $315.0 million to $345.0 million to fund drug discovery and clinical development, further expansion of our manufacturing platform and capabilities, and infrastructure to support our pipeline; approximately $75.0 million to $85.0 million to fund further development of our mRNA technology platform and the creation of new modalities; and the remainder to fund working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Technology Sq.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
At Moderna (Nasdaq: MRNA), we are pioneering the development of a new class of drugs made of messenger RNA (mRNA).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stéphane Bancel
Chief Medical Officer
Tal Zaks
President
Stephen Hoge
VP - General Counsel
Lori Henderson
VP - Manufacturing
Juan Andres
Browse more venture capital transactions:
Prev: 12/6/2018: Pindrop venture capital transaction
Next: 12/6/2018: MetaCX venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs